Osteosarcoma presents significant drug development challenges due to its rarity, the toxicity of current treatments, and the lack of reliable efficacy endpoints. (Shutterstock)
Learn what's happening at the US FDA. On the go.
Derrick Gingery and the team bring you a weekly "Drug Fix".
